COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray
Wayne A
WA
Vanderbilt University School of Medicine, A-1124, MCN, Nashville, TN 37232, USA. wayne.ray@mcmail.vanderbilt.edu
MacDonald
Thomas M
TM
Solomon
Daniel H
DH
Graham
David J
DJ
Avorn
Jerry
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D008565:Membrane Proteins; D009288:Naproxen / Q000009:adverse effects / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib